AteloGene® Local Use in vivo Transfection Kit
Improved gel forming speed and transfection efficiency!!
This in vivo transfection kit is designed for delivering siRNA/miRNA into animal tissues, mouse in particular, to introduce the siRNA/miRNA into cells by local administrations.
Atelocollagen is positively charged and can thus electrostatically form complexes with nucleic acids when they are mixed together at appropriate concentrations and ratios. The complexes protect nucleic acids from being degraded by nucleases in in vivo
Feature and Advantages
- Prolonged in vivoRNAi effect because atelocollagen, the main component of AteloGene® products, form complexes with siRNA/miRNA
- Since AteloGene® products are made from atelocollagen, it is nontoxic.
- AteloGene® Local Use gelates in the body and siRNA/miRNA are slowly released from the gel at the site of administration.
- AteloGene® Local Use “Quick Gelation” has been modified to increase in vivo transfection efficiency by focusing on faster gel formation at the site of administration.
Application
Local administration of nucleic acids
References
- Theranostic application of miR-429 in HER2+ breast cancer.
Cava C, Novello C, Martelli C, Lodico A, Ottobrini L, Piccotti F, Truffi M, Corsi F, Bertoli G, Castiglioni I.
Theranostics. 2020 Jan 1;10(1):50-61. PMID: 31903105 - miR-497-5p mediates starvation-induced death in colon cancer cells by targeting acyl-CoA synthetase-5 and modulation of lipid metabolism.
Gharib E1, Nasri Nasrabadi P1,2, Reza Zali M3.
J Cell Physiol. 2020 Feb 3. [Epub ahead of print] PMID: 32012265 - MiR-1 Suppresses Proliferation of Osteosarcoma Cells by Up-regulating p21 via PAX3.
Fujii R, Osaka E, Sato K, Tokuhashi Y.
Cancer Genomics Proteomics. 2019 Jan-Feb;16(1):71-79. PMID: 30587501 - TWEAK/Fn14 Interaction Confers Aggressive Properties to Cutaneous Squamous Cell Carcinoma.
- Augmented antitumor activity of 5-fluorouracil by double knockdown of MDM4 and MDM2 in colon and gastric cancer cells.
Imanishi M, Yamamoto Y, Wang X, Sugaya A, Hirose M, Endo S, Natori Y, Yamato K, Hyodo I.
Cancer Sci. 2019 Feb;110(2):639-649. PMID: 30488540.
- Theranostic application of miR-429 in HER2+ breast cancer.
RM0.00Price